ThromboGenics Eyes Name Change To Oxurion
Executive Summary
With Jetrea being a disappointment on the commercial front, the Belgian biotech will hope that a new name will augur well for its pipeline of disease modifying compounds for diabetic eye disease.
You may also be interested in...
Deal Watch: Boehringer, Epizyme Team Up To Develop Epigenetic Cancer Therapies
BI and Epizyme’s collaboration will focus on developing novel cancer drugs targeting helicase and HAT enzyme dysregulation. MorphoSys and I-Mab will partner on developing an IO therapy targeting C5aR.
Bausch Health Rises From Valeant's Simmering Ashes
Valeant will change its name to Bausch Health beginning in July and get a new ticker symbol, BHC, as the new management team looks to leave the company's checkered past behind.
Deal Watch: Are Ultragenyx, REGENXBIO In A Bidding War For Dimension?
ProQR spinout Amylon gets started by licensing four central nervous system disorder candidates from its parent, while start-up Eyevance gets US rights to Nicox’s Zerviate.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports